RTP Mobile Logo
Hematologic Oncology Update, Issue 1, 2016 (Video Program)
Released August 2016

Proceedings from video interviews with Drs Anas Younes, B Douglas Smith, Rafael Fonseca and John P Leonard on the treatment of hematologic cancers.

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY
    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity will assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and relapsed/refractory Hodgkin lymphoma.
    • Reevaluate current treatment approaches for patients with myeloproliferative disorders and acute and chronic leukemias in light of newly emerging clinical data.
    • Recognize the recent FDA approvals of daratumumab, elotuzumab, ixazomib and panobinostat, and identify where and how these agents should be integrated into the clinical management of relapsed or refractory multiple myeloma.
    • Assess approved and investigational treatment options for patients with mantle-cell lymphoma.
    • Appreciate the recent FDA approval of venetoclax as treatment for patients with relapsed/refractory chronic lymphocytic leukemia and deletion 17p, and discern how this therapy can be appropriately integrated into the clinical management of this disease.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/HOU116/Video/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Anas Younes, MD
    Chief, Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Contracted Research: Curis Inc, Johnson & Johnson Pharmaceuticals, Novartis Pharmaceuticals Corporation; Honoraria: Incyte Corporation, Janssen Biotech Inc; Other Remunerated Activities: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Merck, Takeda Oncology.

    B Douglas Smith, MD
    Professor of Oncology
    Division of Hematologic Malignancies
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Advisory Committee: Applied Bioscience, Bristol-Myers Squibb Company; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Sanofi; Contracted Research: Amgen Inc, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cephalon Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Hodgkin Lymphoma
Prognostic tools in Hodgkin lymphoma (HL)
Brentuximab vedotin as initial salvage treatment on first relapse in HL
Brentuximab vedotin as consolidation therapy for patients with HL at high risk of disease progression after autologous stem cell transplant (ASCT)
Side effects and durability of response with brentuximab vedotin
Monitoring patients with HL who achieve a complete response with brentuximab vedotin
Correlation between PD-L1 expression and response to anti-PD-1 antibodies in HL
Investigating the combination of brentuximab vedotin and an immune checkpoint inhibitor for advanced HL
ECHELON-1: A Phase III trial evaluating doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) versus brentuximab vedotin, doxorubicin, vinblastine and dacarbazine as front-line therapy for advanced classical HL
Diffuse Large B-Cell Lymphoma and T-Cell Lymphoma
Prognostic significance of diffuse large B-cell lymphoma cell of origin
Management of T-cell lymphomas
Activity of the FLT3 inhibitors midostaurin and sorafenib in acute myeloid leukemia (AML)
Novel investigational agents for FLT3-ITD mutation-positive AML, including gilteritinib (ASP2215)
Myelodysplastic Syndromes and Myeloproliferative Disorders
Schedule of demethylating agents and use of lenalidomide for myelodysplastic syndromes
Choice of first-line tyrosine kinase inhibitor therapy in chronic myeloid leukemia (CML) and role of generic imatinib
Treatment patterns, overall survival, healthcare resource use and costs for elderly patients with CML
Choosing between dasatinib and nilotinib for patients with higher-risk CML
When to intervene in myeloproliferative neoplasms: Clinical indications for ruxolitinib
Multiple Myeloma
Available research data with carfilzomib- and bortezomib-based induction therapy for patients with multiple myeloma (MM)
Integration of the newly FDA-approved oral proteasome inhibitor ixazomib into clinical practice
Perspective on the use of panobinostat for relapsed/refractory MM
Incorporation of the newly FDA-approved monoclonal antibody elotuzumab into the therapeutic algorithm for MM
Clinical experience with the newly FDA-approved monoclonal antibody daratumumab
Monitoring and management of smoldering myeloma
Chronic Lymphocytic Leukemia
Viewpoint on efficacy and long-term outcomes with fludarabine/cyclophosphamide/ rituximab (FCR) versus bendamustine/rituximab (BR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL)
Use of the newly FDA-approved Bcl-2 inhibitor venetoclax in CLL
Incorporation of venetoclax into the treatment algorithm for patients with del(17p) CLL
Mantle-Cell Lymphoma
Lenalidomide and rituximab (R2) as initial treatment for mantle-cell lymphoma (MCL)
Activity and tolerability of ibrutinib/palbociclib in relapsed/refractory MCL
Updated results of the Phase II SWOG-S1106 trial of R-hyper-CVAD versus BR followed by ASCT for MCL